F-18-fluorothymidine - National Cancer Institute

Drug Profile

F-18-fluorothymidine - National Cancer Institute

Alternative Names: 18-F-fluorothymidine; 18F-FLT - National Cancer Institute; 18F-fluorothymidine - National Cancer Institute; 3'-deoxy-3'-[18F] Fluorothymidine PET/CT scanning - National Cancer Institute; F-18-FLT; Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) - National Cancer Institute

Latest Information Update: 25 Aug 2015

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer National Cancer Institute (USA); Radboud-University-Nijmegen-Medical-Centre; University of Washington
  • Class Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Glioma
  • No development reported Cancer metastases

Most Recent Events

  • 25 Aug 2015 Clinical development for Glioma (diagnosis) is ongoing in the USA
  • 25 Aug 2015 F-18-fluorothymidine is still in phase II trials for Breast cancer (Diagnosis) in the USA
  • 03 Feb 2014 Case Comprehensive Cancer Center and National Cancer Institute plan a clinical trial for Solid tumours (diagnosis) in USA (NCT02055586)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top